Abstract 4298: the Gut Microbiome is Associated with Clinical Responses to Anti-Pd-1 Immunotherapy in Gastrointestinal Cancer Patients in China
Zhi Peng,Siyuan Cheng,Quan Zhang,Yan Kou,Ziqi Wang,Rong Jin,Han Hu,Xiaotian Zhang,Jifang Gong,Jian Li,Ming Lu,Xicheng Wang,Jun Zhou,Zhihao Lu,Dongtao Bi,Yan Tan,Lin Shen
DOI: https://doi.org/10.1158/1538-7445.am2020-4298
IF: 11.2
2020-01-01
Cancer Research
Abstract:Abstract We report the first and largest cohort, to the best of our knowledge, on the gut microbiome of 126 gastrointestinal (GI) cancer patients in China receiving the immune checkpoint inhibitors (ICI) targeting PD-1. The cohort included 31 patients with colon cancer, 23 with esophageal carcinoma, 47 with gastric cancer, and 25 with other cancer types. 43 of the patients had samples collected before treatment. 35 of patients were assessed as microsatellite-instability-High (MSI-High) and 71 as non-MSI-High. 408 fecal samples from the patients were collected. We performed 16s rRNA amplicon sequencing (V4 region) of the patients' samples to investigate the relationship between microbial profiles and patients' immunotherapy treatment response (RECIST 1.1). Principal coordinate analysis (PCoA) showed a subgroup of responders exhibiting a microbiome profile which was enriched in Prevotella. Hierarchical clustering of patients' microbiome profiles also suggested that for each gastric and colon cancer, patients with the same response tend to share similar microbiome profiles. By comparing the microbiome profiles between R and NR group using samples collected before treatment or within 3 weeks since the start of treatment, we identified 16s rRNA V4 sequences from Prevotella enriched in R group for each tumor type, which suggests positive association between Prevotella and tumor response. Our data also suggested that MSI as good marker for tumor response, although more data is required to achieve the significance level. Besides, no significant difference in alpha diversity was observed between R and NR group for each tumor type. In sum, we studied the microbiome profiles of 126 GI cancer patients and evaluated their association with anti-PD-1 immunotherapy. Patients with the same tumor type and response tend to share similar microbiome profiles, where Prevotella and a few other taxa contributed to the pattern. Citation Format: Zhi Peng, Siyuan Cheng, Quan Zhang, Yan Kou, Ziqi Wang, Rong Jin, Han Hu, Xiaotian Zhang, Jifang Gong, Jian Li, Ming Lu, Xicheng Wang, Jun Zhou, Zhihao Lu, Dongtao Bi, Yan Tan, Lin Shen. The gut microbiome is associated with clinical responses to anti-PD-1 immunotherapy in gastrointestinal cancer patients in China [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4298.